254 related articles for article (PubMed ID: 36877373)
21. An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor.
Kim RS; Yaghy A; Wilde LR; Shields CL
JAMA Ophthalmol; 2020 Apr; 138(4):418-419. PubMed ID: 32163103
[No Abstract] [Full Text] [Related]
22. FLT3 Inhibition in Acute Myeloid Leukemia.
Smith CC
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S5-S6. PubMed ID: 32862867
[TBL] [Abstract][Full Text] [Related]
23. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
Kiyoi H; Kawashima N; Ishikawa Y
Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
[TBL] [Abstract][Full Text] [Related]
24. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.
Yilmaz M; Daver N
Drugs; 2019 Jul; 79(11):1177-1186. PubMed ID: 31222627
[TBL] [Abstract][Full Text] [Related]
25. New Treatment Options for Acute Myeloid Leukemia in 2019.
Cerrano M; Itzykson R
Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
[TBL] [Abstract][Full Text] [Related]
26. FLT3 mutations in myeloid sarcoma.
Ansari-Lari MA; Yang CF; Tinawi-Aljundi R; Cooper L; Long P; Allan RH; Borowitz MJ; Berg KD; Murphy KM
Br J Haematol; 2004 Sep; 126(6):785-91. PubMed ID: 15352981
[TBL] [Abstract][Full Text] [Related]
27. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Garcia JS; Stone RM
Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
[TBL] [Abstract][Full Text] [Related]
28. A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia.
Yoshiki Y; Asai T; Ichikawa M; Hangaishi A; Ota S; Imai Y; Takahashi T; Kurokawa M
Intern Med; 2011; 50(21):2649-52. PubMed ID: 22041374
[TBL] [Abstract][Full Text] [Related]
29. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract][Full Text] [Related]
30. Acute Myeloid Leukemia Mutations: Therapeutic Implications.
Papayannidis C; Sartor C; Marconi G; Fontana MC; Nanni J; Cristiano G; Parisi S; Paolini S; Curti A
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31163594
[TBL] [Abstract][Full Text] [Related]
31. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Stone RM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
[TBL] [Abstract][Full Text] [Related]
32. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
33. Mass-forming neoplastic extramedullary hematopoiesis mimics myeloid sarcoma in a patient with chronic phase chronic myeloid leukemia.
Hu Z; Singhi EK; Apostolidou E; Mai B; Juneja HS; Hu S
Int J Lab Hematol; 2021 Jun; 43(3):e135-e137. PubMed ID: 33314782
[No Abstract] [Full Text] [Related]
34. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
35. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
Brinton LT; Zhang P; Williams K; Canfield D; Orwick S; Sher S; Wasmuth R; Beaver L; Cempre C; Skinner J; Cannon M; Govande M; Harrington B; Lehman A; Byrd JC; Lapalombella R; Blachly JS
J Hematol Oncol; 2020 Oct; 13(1):139. PubMed ID: 33076970
[TBL] [Abstract][Full Text] [Related]
36. Acute myeloid leukemia concurrent with spinal epidural extramedullary myeloid sarcoma accompanied by a high CD25 expression and the FLT3-ITD mutation.
Isshiki Y; Ohwada C; Togasaki E; Shimizu R; Hasegawa N; Yamazaki A; Sugita Y; Kawaguchi T; Tsukamoto S; Sakai S; Takeda Y; Takeuchi M; Sakaida E; Shimizu N; Ota S; Yokote K; Iseki T; Nakaseko C
Intern Med; 2014; 53(11):1159-64. PubMed ID: 24881741
[TBL] [Abstract][Full Text] [Related]
37. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
38. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
Fathi AT; Chen YB
Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291
[TBL] [Abstract][Full Text] [Related]
39. [Genetic analysis and targeted therapy for acute myeloid leukemia].
Yamaguchi H
Rinsho Ketsueki; 2020; 61(4):350-357. PubMed ID: 32378580
[TBL] [Abstract][Full Text] [Related]
40. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.
Sami SA; Darwish NHE; Barile ANM; Mousa SA
Curr Treat Options Oncol; 2020 Jan; 21(1):3. PubMed ID: 31933183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
